INNOVADERM CRO IS NOW INDERO.
READ THE ANNOUNCEMENT
Talk to us

Streamline your Drug Development Journey with Indero’s Clinical/Regulatory Consulting Services

Audrey Miron

Audrey Miron

Associate Director, Business Development

Author picture

Did you know that as part of our comprehensive service portfolio, we continuously offer clinical/regulatory dermatology consulting services?

Innovaderm is proud to announce its partnership with RegDev, Inc., a leading regulatory consultancy firm. With a 100% inspection approval rate for NDA/BLA submissions under their belt, RegDev, Inc. is a pioneer in regulatory services, and the perfect collaborator to help us offer our clients unmatchable regulatory support.

Leveraging the clinical proficiency of Innovaderm and the recognized regulatory success of RegDev, we can provide you with the finest clinical/regulatory consulting services available on the market.

Whether you are aiming to penetrate the US or EU markets, require regulatory submission support, or simply need clinical/regulatory guidance, our expert teams will assist you through these critical tasks, helping to guide you through the regulatory process to position your product for success!

Let us show you how we can make your clinical & regulatory drug development journey easier and faster.

SHARE THIS POST

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

This field is for validation purposes and should be left unchanged.
Talk to us

Jeff Smith

Chef de la direction

Jeff Smith, Chef de la direction d’Indero Recherches, apporte près de 30 ans d’expérience dans l’industrie pharmaceutique et CRO, s’étant distingué par son leadership exceptionnel, sa vision stratégique et son innovation. L’expertise de Jeff couvre des opérations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matière de création de valeur, de gestion des partenaires et d’opérations CRO ont toujours contribué au succès dans ses fonctions précédentes. Sous la direction de Jeff, Indero continue d’étendre ses capacités, faisant progresser les connaissances médicales et les nouvelles thérapies en dermatologie et en rhumatologie.

Revolutionize Your Topical Trials

Efficacy insights in days, not months.

 Indero’s Early Phase 1 model enables sponsors to initiate topical studies that detect early pharmacodynamic signals much sooner than traditional phase 1, using microdosing and transcriptomic analysis. This approach reduces preclinical requirements, shortens study duration from 8–12 weeks to ≤3 days, and lowers costs, helping teams make informed go/no-go decisions faster.
LEARN MORE >